Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 20 for “"Lucentis"”.
-
Monoclonal Antibody Separation: Lucentis from Genentech
… design project focuses on the bioseparation of Lucentis (Genentech Inc.), a humanized anti-VEGF-A monoclonal antibody fragment used to treat macular degeneration. Vascular endothelial growth factor, VEGF, promotes blood vessel growth in the wet form of macular degeneration. These fragile blood …
-
Optimization of Downstream Purification of Lucentis
… and purification of the fragmented antibody, Lucentis, was explored and compared to several alternative cases that were hypothesized to optimize the purification process. The base case consisted of using a series of chromatography columns including anion exchange, cation exchange, and …
-
Tangential Flow Filtration for the Purification of Lucentis
… to design a process to manufacture and purify a "Lucentis®-like" (Lu-L) protein. This group has been working on the tangential flow filtration (TFF) portion of the project, which will be utilized multiple times throughout the separation and purification process. The primary purpose of tangential …
-
Behandlung der neovaskulären altersabhängigen Makuladegeneration mit Ranibizumab (Lucentis) im klinischen Alltag
Die gegenwärtige Behandlung der neovaskulären AMD mit 0,5 mg Ranibizumab besteht aus einer 3-monatigen Aufsättigungsphase und einer bedarfsabhängigen Erhaltungsphase. Die vorliegende nicht interventionelle Studie hatte zum Ziel, während des 12-monatigen Beobachtungszeitraums das Behandlungsschema …
-
Αντιμετώπιση του οιδήματος της ωχράς λόγω απόφραξης κεντρικής φλέβας αμφιβληστροειδούς με ενδοϋαλοειδική έγχυση του αντι-αγγειογενετικού παράγοντα ranibizumab (lucentis)
… repeated intravitreal injections of ranibizumab(Lucentis) on visual acuity (VA) and central foveal thickness (CFT) for central retinal vein occlusion (CRVO)-induced macular edema.Methods: Our study was a prospective interventional case series. Twelve eyes of 12 consecutive patientsdiagnosed with …
-
Optimization of Downstream Processing of a Monoclonal Antibody
… Reno on the antibody separation processes for Lucentis. Lucentis is a humanized anti vascular endothelial growth factor (VEGF) monoclonal antibody fragment used to treat macular degeneration. VEGF promotes blood vessel growth in the wet form of macular degeneration which leads to bleeding …
-
Genentech: Purification of Monoclonal Antibody
Lucentis, a monoclonal antibody fragment produced in Escherichia coli, is used to treat wet age-related macular degeneration, one of the leading causes of legal blindness. The objective of this thesis is to analyze the process of antibody fragment separation and to purify a solution of "Lucentis …
-
Genentech Senior Design Project: Purification of a Ranibizumab-like Protein
… monoclonal antibody similar to Ranibizumab, or "Lucentis", which is used in the treatment of wet age-related macular degeneration of the eyes, a leading cause of blindness. A focus on the chromatographical purification of Lucentis is provided, and both base and alternate cases for a complete …
-
Genentech: Cell Fermentation
A challenge to grow E. coli and express a Lucentis-like protein of interest in the laboratories of the Department of Chemical and Materials Engineering at the University of Nevada, Reno is presented by Genentech. A potential model to achieve this goal is created involving a bioreactor hosted in the …
-
Vergleich von intravitrealem Dexamethason-Implantat mit intravitrealem Ranibizumab zur Behandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen
… vorzubeugen gilt. Mittlerweile sind Lucentis® als Anti-VEGF-Inhibitor sowie Ozurdex® als Steroid-Implantat (Dexamethason) zur Behandlung des Makulaödems bei venösen Gefäßverschlüssen zugelassen und stellen in der Therapie von RVV neben der konventionellen Laserbehandlung eine …
-
Biosynthesis of polyhydroxyalkanoates and their medical applications
… were encapsulated with three model proteins BSA, Lucentis® and RNase A to understand the effect of morphology, drug distribution on the in vitro release profiles. The microspheres produced were of an average size of 2μm. P(3HB) microspheres investigated for use as drug delivery vehicles in the …
-
Reakcja ekosystemu wodnego na zabiegi rekultywacyjne na przykładzie Jeziora Swarzędzkiego
… przed degradacją zbiornika – Potametum lucentis. Zmiany te wynikały ze zwiększenia zasięgu promieniowania słonecznego oraz zmniejszenia stężeń nutrientów. Stwierdzono też skrócenie okresu beztlenowego w warstwie naddennej oraz obniżenie koncentracji azotu oraz fosforanów przy dnie …
-
Erfahrungen mit intravitrealem Bevacizumab (Avastin®) bei exsudativer, altersabhängiger Makuladegeneration
… Makuladegeneration. Mit der Zulassung von Lucentis Ende Januar 2007 und regelmäßigen Injektionen kam es zu einer Änderung der Therapieoptionen der CNV bei exsudativer AMD. Die Einjahres- und Zweijahresergebnisse der CATT- Studien zeigten, dass sich Lucentis und Avastin nicht signifikant …
-
Comparison of Tissue Contractile Responses of Rat Models of Pulmonary Artery Hypertension and Type I/II Diabetes
… that will purify a monoclonal antibody (Lucentis) grown and extracted from e. coli for the purpose of treating the "wet" form of macular degeneration. The following units will be explored, in this determined order: homogenizer, centrifuge, column chromatography, tangential flow …
-
Development of polymeric nanoparticulate formulation encapsulating protein molecules following hydrophobic ion pairing complexation
… parameters with IgG-Fab fragment, ranibizumab (Lucentis®), an anti-VEGF antibody fragment used for the treatment of age-related macular degeneration, loaded nanoparticulate formulation was also successfully developed. Developed nanoparticles formulations were characterized with respect to …
-
Die Rolle von löslichen Faktoren bei der Hemmung der T-Zell-Aktivierung durch humane retinale Pigmentepithelzellen
… Bevacizumab (Avastin™, Roche) und Ranibizumab (Lucentis™, Novartis) auf die Hemmung der T-Zell-Proliferation durch humane RPE-Zellen geprüft. <br>Methode: Humane T-Lymphozyten von verschiedenen Spendern wurden in Ko-Kulturen mit den humanen RPE-Zelllinien ARPE-19 und M154 mit anti-CD3- und …
-
Ο ρόλος των αντινεοαγγειακών παραγόντων στο διαβητικό οίδημα της ωχράς
… the advent of the anti-VEGF therapy ranibizumab (Lucentis, Genentech) for diabetic macular edema (DME) The most significant effect that the RISE and RIDE data have had is that patients with center-involving DME have a good chance of substantially improving their vision vs what was possible with …
-
Einfluss der initialen Therapiestrategie zur Behandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen auf die Ergebnisse – Vergleich von intravitrealen Anti-VEGF-Präparaten mit einem intravitrealen Dexamethason-Implantat unter Alltagsbedingungen
… occlusion (RVO). VEGF inhibitors – ranibizumab (Lucentis®), aflibercept (Eylea®), bevacizumab (Avastin®, off-label) – and a dexamethasone implant (Ozurdex®) are used in Germany to treat macular edema from RVO. Aim. The aim of the study was to investigate the effect of the initial drug choice on …
-
Διερεύνηση της γενετικής βάσης στην αντιμετώπιση της ηλικιακής εκφύλισης της ωχράς κηλίδας
… injections with a dose of 0.5 mg ranibizumab (Lucentis®). Treatment response was evaluated by comparing visual acuity and optical coherence tomography (OCT) between baseline and the end of the treatment. Patients were classified as responders and non-responders based on OCT and visual acuity …